Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-20-018057
Filing Date
2020-04-23
Accepted
2020-04-23 08:30:33
Documents
4
Period of Report
2020-06-08
Effectiveness Date
2020-04-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A agle-def14a_20200608.htm DEF 14A 691914
2 GRAPHIC ggmfp314tr5p000003.jpg GRAPHIC 68394
3 GRAPHIC ggmfp314tr5p000001.jpg GRAPHIC 1931
4 GRAPHIC ggmfp314tr5p000002.jpg GRAPHIC 65985
  Complete submission text file 0001564590-20-018057.txt   881097
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 20809242
SIC: 2834 Pharmaceutical Preparations